98165-65-2

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 5-(bromomethyl)-2-methoxy-, methyl ester is used as a synthetic intermediate for the production of various pharmaceuticals. Its unique chemical structure allows it to be a versatile building block in the synthesis of a wide range of medicinal compounds.
Used in Organic Chemistry:
In the field of organic chemistry, Benzoic acid, 5-(bromomethyl)-2-methoxy-, methyl ester is used as a reagent and intermediate in the synthesis of various organic compounds. Its bromomethyl group can be used for further functionalization, making it a valuable component in organic synthesis.

Upstream product

• 558-13-4 carbon tetrabromide 
• 191604-81-6 methyl 5-(hydroxymethyl)-2-methoxybenzoate 
• 78515-16-9 methyl 5-formyl-2-methoxybenzoate 
• 67-56-1 methanol 
• 25045-36-7 2-methoxy-5-methylbenzoic acid 

Downstream Products

• 865757-45-5 C₉H₉BrO₃ 
• 10286-57-4 2-Methoxy-5-(hydroxymethyl)benzoesaeure 
• 900641-76-1 methyl 5-(aminomethyl)-2-methoxybenzoate 
• 1616491-35-0 6-iodo-1-(4-methoxy-3-(methoxycarbonyl)benzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1616491-36-1 1-(4-hydroxy-3-(methoxycarbonyl)benzyl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1616491-37-2 methyl-5-((3-(benzylcarbamoyl)-6-iodo-4-oxoquinolin-1(4H)-yl)methyl)-2-methoxybenzoate 
• 1429646-88-7 methyl 5-((4-chloro-N-(tetrahydro-2H-pyran-4-yl)phenylsulfonamido)methyl)-2-methoxybenzoate 
• 1429646-98-9 5-((4-chloro-N-((tetrahydro-2H-pyran-4-yl)methyl)phenylsulfonamido)methyl)-2-methoxybenzoic acid 
• 1429646-97-8 methyl 5-((4-chloro-N-((tetrahydro-2H-pyran-4-yl)methyl)phenylsulfonamido)-methyl)-2-methoxybenzoate 
• 1372175-57-9 (R)-methyl 5-((4-chloro-N-(2-hydroxy-1-phenylethyl)phenylsulfonamido)methyl)-2-methoxybenzoate 
• 104447-87-2 5-[6-(2-Ethyl-hexanoylamino)-indol-1-ylmethyl]-2-methoxy-benzoic acid methyl ester 

Relevant academic research and scientific papers

An HDAC8-selective fluorescent probe for imaging in living tumor cell lines and tissue slices

Histone deacetylase 8 (HDAC8) has been used as a therapeutic target for many cancers as it is highly expressed in neuroblastoma cells and breast cancer cells. HDAC8-selective fluorescent probes need to be urgently developed. Herein, two novel fluorescent probes, namelyNP-C6-PCIandAM-C6-PCI, based on the conjugation of 1,8-naphthalimide with a highly selective inhibitor of HDAC8 (PCI-34051) were reported. Compared withPCI-34051(KD= 6.25 × 10?5M),NP-C6-PCI(KD= 8.05 × 10?6M) andAM-C6-PCI(KD= 7.42 × 10?6M) showed great selectivity toward HDAC8. Two fluorescent probes exhibited high fluorescence intensity underλex= 450 nm and a large Stokes shift (100 nm).NP-C6-PCIwas selected for cell and tissue imaging due to the similarity in the bioactivity ofNP-C6-PCIwithPCI-34051. The ability ofNP-C6-PCIto target imaging HDAC8 in SH-SY5Y and MDA-MB-231 tumor cells was demonstrated. Furthermore,NP-C6-PCIwas applied to imaging SH-SY5Y tumor tissue slices to indicate the relative expression level of HDAC8. Therefore, this HDAC8-selective fluorescent probe can be expected for applications in HDAC8-targeted drug screening as well as in pathologic diagnoses.

NOVEL ADENINE COMPOUND AND USE THEREOF

A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene; etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents -COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.

Indazole compounds, pharmaceutical compositions and use

The invention provides a series of novel heterocyclic amides of the formula I in which the group A CRa can be --CRb=CRa--, --CHRb--CHRa-- or --N=CRa--, the amidic group Re.L can be Re.X.CO.NH, Re.X.CS.NH or Re.NH.CO attached at position 4, 5 or 6 of the benzenoid moiety, Z is an acid group selected from the group consisting of carboxy, an acylsulphonamide residue of the formula CO.NH.SOn Rg and a tetrazolyl residue of the formula II, and the radicals Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, n, X, G1, Q and G2 have the meanings defined in the following specification. The compounds of formula I are leukotriene antagonists. The invention also provides pharmaceutically acceptable salts of the formula I compounds; pharmaceutical compositions containing the formula I compounds, or their salts, for use in the treatment of, for example, allergic or inflammatory diseases, or endotoxic or traumatic shock conditions; and processes for the manufacture of the formula I compounds, as well as intermediates for use in such manufacture.